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Summary The serine/threonine kinase Akt, a downstream
effector of phosphatidylinositol 3-kinase (PI3K), is in-
volved in cell survival and anti-apoptotic signaling. Akt
has been shown to be constitutively expressed in a variety
of human tumors including hepatocellular carcinoma
(HCC). In this report we analyzed the status of Akt
pathway in three HCC cell lines, and tested cytotoxic
effects of Akt pathway inhibitors LY294002, Wortmannin
and Inhibitor VIII. In Mahlavu human hepatoma cells Akt
was constitutively activated, as demonstrated by its Ser473
phosphorylation, downstream hyperphosphorylation of
BAD on Ser136, and by a specific cell-free kinase assay.
In contrast, Huh7 and HepG2 did not show hyperactivation
when tested by the same criteria. Akt enzyme hyper-
activation in Mahlavu was associated with a loss of PTEN
protein expression. Akt signaling was inhibited by the
upstream kinase inhibitors, LY294002, Wortmannin, as
well as by the specific Akt Inhibitor VIII in all three
hepatoma cell lines. Cytotoxicity assays with Akt inhibitors
in the same cell lines indicated that they were all sensitive,
but with different IC50 values as assayed by RT-CES. We
also demonstrated that the cytotoxic effect was through
apoptotic cell death. Our findings provide evidence for its
constitutive activation in one HCC cell line, and that HCC
cell lines, independent of their Akt activation status respond
to Akt inhibitors by apoptotic cell death. Thus, Akt
inhibition may be considered as an attractive therapeutic
intervention in liver cancer.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide occurs in patients with chronic viral
hepatitis and cirrhosis at a high rate (3–5% annually) and is
a major cause of morbidity and mortality in patients with
advanced liver disease [1]. In healthy individuals, liver is a
quiescent organ and adult hepatocytes are nondividing cells
under normal physiological conditions. However, chronic
liver injury due to viral diseases, exposure to chemicals and
other environmental or host factors results in extensive cell
death and consequently hepatocyte proliferation [2]. Chronic
cell death in liver leads to a state where continuous
hepatocyte regeneration is observed as a result of the
inflammatory response. Continuous cycles of liver cell death
and proliferation induce many cell signaling pathways
including cell survival pathways such as Akt [3, 4].
Knowledge on the signaling pathways and the alterations
involved in HCC is extending, however their role in
molecular targeted therapy still remains to be described.
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The most promising molecular targets in the generation of
new chemotherapy agents are the protein kinases, including
those in the PI3K/Akt pathway. The Akt pathway is involved
in many cancers, as well as HCC development, through its
activation by EGF or IGF signaling or the constitutive
activation of Akt proteins or the inactivation of PTEN tumor
suppressor [5–8]. The serine/threonine kinase Akt is a well-
characterized downstream target of PI3K and resides within
the cytoplasm in an inactive state, but binding of PtdIns
(3,4,5)P3 to its pleckstrin homology (PH) domain recruits
Akt to the plasma membrane and enables its activation by
phosphorylation on the C-terminal hydrophobic tail [9].
Once activated, signaling through Akt can be propagated to a
diverse array of substrates. Activated Akt is known to inhibit
apoptosis through its ability to phosphorylate several targets,
including BAD, FoxO transcription factors, Raf-1 and
caspase-9, which are critical for cell survival [9]. Moreover,
the tumor suppressor protein PTEN prevents Akt activation
by acting as a lipid phosphatase on the PI3K product PtdIns
(3,4,5)P3. Akt pathway hyper-activation has been reported
due to the loss of tumor suppressor protein PTEN function
through mutations, deletions, or epigenetic silencing [10, 11].
The PTEN gene is the second most frequently modified
tumor suppressor gene, and is related to many cancers
including brain, bladder, breast, prostate, endometrial and
liver cancer [10–12].
In primary liver carcinoma, one of the major pathogenic
mechanisms resides in the activated intracellular signal
transduction caused by oncogenes and the tumor suppressor
gene dysfunction that stimulates cell-cycle progression and
enhance cell survival [13]. Despite this much information, the
behavior and relevance of the Akt pathway in HCC and its
therapeutic potential remain to be further elucidated. Since
liver cancer usually develops on the background of chronic
liver disease, conventional anticancer therapies are not
effective. Moreover, the chemotherapeutics currently in use
are non-selective cytotoxic drugs that can lead to systemic
side effects in HCC patients with compromised liver function.
Recently, Sorafenib, a multikinase inhibitor acting through
VEGFR and PDGFR of the Raf kinase pathway, was
approved for hepatocellular carcinoma treatment [4]. The
Sorafenib Hepatocellular Carcinoma Assessment Random-
ized Protocol (SHARP) three-year clinical trial included 602
advanced-stage HCC patients (ClinicalTrials.gov number,
NCT00105443) [4]. The average survival rate for the group
taking Sorafenib was 10.7 months, and that for the group
taking the placebo was 7.9 months. For the Sorafenib group a
one-year survival rate of 44% was observed, whereas it was
33% for the placebo group. FDA- and EU- approved
chemotherapeutic Sorafenib thus prolongs median survival
and the time to progression by nearly three months in patients
with advanced hepatocellular carcinoma. Therefore FDA and
EU approved chemotherapeutic Sorafenib prolongs median
survival and the time to progression by nearly 3 months in
patients with advanced hepatocellular carcinoma. Therefore,
there is a need for new liver cancer specific drugs based on
the molecular mechanisms involved in liver carcinogenesis.
In this study, we investigated the Akt activation status in
HCC cell lines the differential effects of three Akt pathway
inhibitors and the extent of the inhibition of Akt signaling
as a major molecular mechanism in determining inhibitor-
induced apoptosis in these cells. The Akt pathway can be
blocked by cell line specific doses of pathway inhibitors.
Therefore, our findings suggested that PI3K/Akt could
represent an attractive target mitigating in liver cancer.
Materials and methods
Materials
DMEM (cat.12-614F), FCS (cat.DE 14-801F), antibiotics
(cat.DE 17-602E), glutamine and non essential amino acids
(cat.BE 13-114E) were from Lonza (Milan). Calnexin, β-
actin antibody, and Sulforhodamine B (SRB) (cat.86183-
5 g) were from Sigma (St. Louis, MO). Lumi-Light
detection kit (cat.12 015 196001) was from Roche M.B.
(Germany). Akt Inhibitor VIII (cat.124018), Wortmannin
(cat. BML-ST415-0005) and LY294002 (cat.440202) were
from Calbiochem (La Jolla, CA). The DMSO concentration
for drug solubilization was always less than 1% in the cell
culture medium.
The Akt Antibody (cat.610861) was from BD Transduc-
tion Laboratories (Franklin Lakes, NJ) and anti-p-473Ser
Akt (cat.587F11), anti-BAD (cat.185D10), anti-p-BAD
(cat.#9292), recGSK3α/β fusion protein (cat.#9237 L),
anti-p-GSK3α/β (cat.#9331 L), anti-PTEN and anti-PARP
(cat.46D11) antibodies were from Cell Signaling (Danvers,
MA). The immunoprecipitation matrix (cat.sc-45042) was
from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture
Hepatoma cells (Huh7, HepG2, Mahlavu) were cultured at
37°C, 5% CO2 in standard medium (2 mML-Glutamine,
0.1 mM NEA, 1xPS in DMEM) with 10% FCS.
Western blotting analysis
Proteins, from cells grown to 60–70% confluence, were
separated on 10% SDS-PAGE, transferred onto nitrocellu-
lose membranes and visualized as described previously [14].
1304 Invest New Drugs (2011) 29:1303–1313
Akt kinase activity assay
Total homogenates from cells were resuspended in 50 mM
Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 150 mM
NaCl, 1% Triton X-100, 0.1% SDS plus phosphatase and
proteases inhibitors. IP was performed according to the
manufacturer’s instruction. Akt IP was resuspended in
20 mM HEPES pH 7.4, 10 mM MgCl2 and 10 mM MnCl2.
The reaction was started by incubating 10 μl IP, 100 μM
ATP and 1 μg recGSK3α/β for 40 min at RT, and then
stopped by 1 M Tris-HCl pH 6.8, 8% SDS, 40% glycerol,
20% β-ME. GSK3α/β phosphorylation was detected by
western blotting.
NCI-60 Sulforhodamine B (SRB) cytotoxicity assay
The cytotoxicities of LY294002, Akt Inhibitor VIII and
Wortmannin were tested as previously described [15].
Hepatoma cells (5000) were inoculated into 96 well
plates,100 μl/well. Next day, inhibitors with the indicated
concentrations were applied in a total of 200 μl of
medium. After 72 h of treatment, cells were fixed by cold
10% (w/v) TCA and then the wells were washed and
dried. One hundred μl of 0.4% SRB dye was applied to
each well and incubated at RT for 10 min then removed
and wells were dried. SRB dye was solubilized in 200 μl
10 mM Tris-Base and the absorbance was measured at
515 nm.
Real-time cell growth surveillance by cell electronic
sensing
Hepatoma cells (2000cell/well in 150 μl) were inoculat-
ed into 96 E-Plates (Roche) containing 50 μl medium/
well. Proliferation was monitored in real-time cell
electronic sensing RT-CES (xCELLigence-Roche Ap-
plied Science), and the cell index (CI) was measured
every 30 min for 24 h [16]. Next day, 100 μl medium
was discarded and 50 μl fresh medium was added to each
well. Inhibitors with indicated concentrations were ap-
plied to150 μl of medium. CI values were taken every
10 min for 4 h to visualize the fast drug response and then
every 30 min to visualize the long-term drug response.
Impedance measurements are displayed as Cell Index (CI)
values and the effect of the inhibitors on cell growth is
calculated as CIDRUG/CIDMSO. When the cells adhered to
electrodes on the bottom of the wells, CI values increased
in parallel to the cell growth due to the insulating
properties of the cell membrane. As the number of cells
covering the electrodes increases the electrical impedance
(Z) increased (Z0=0 --->Z=Zcell).
Fluorescence microscopy
Cells were seeded at 3×104 cells/cm2 on coverslips,
allowed to grow for 24 h, as indicated in the figure
legends, then washed twice with PBS and fixed with 4%
paraformaldehyde. Subsequently, cells were washed once
more with PBS and stained with 0.5 mg/ml DAPI.
Preparations were dehydrated with increasing concentra-
tions of ethanol and embedded in glycerol containing the
antifading agent to be analyzed with Zeiss Axiophot
epifluorescence microscope coupled with a Photometric
Cool Snap CCD camera for image acquisition. The
percentage of apoptotic cells was determined by counting
fragmented nuclei in a minimum of 4 fields containing at
least 150 cells. These experiments were performed in
triplicate. As a positive control for apoptosis, cells were
treated with 100 ng/ml Doxorubicine.
RT-PCR
Total RNA was isolated with NucleoSpin RNA II Kit (MN,
Germany). cDNAs synthesized from 4 μg RNA with
RevertAid kit (MBI Fermentas, Lithuania) were amplified
by PCR with the primers (PTEN: intron-3-F_5´-AAAGATT
CAGGCAATGTTTGTT-3´, intron-4-R_5´-TCTCACTCGA
TAATCTGGATGAC-3´, exon-4-F_5´-GACATTATGA
C A C C G C C A A A - 3 ´ , e x o n - 5 - R _ 5 ´ - T T C G
TCCCTTTCCAGCTTTA-3´, exon-7-F_5´-CGACGGGAA
GACAAGTTCAT- 3 ´ , e x o n - 8 - R _ 5 ´ AGGTTT
CCTCTGGTCCTGGT-3´, and GAPDH: F-5´-GGCTGA
GAACGGGAAGCTTGTCAT-3´ and R-5´CAGCCTTCTC
CATGGTGGTGAAGA-3´).
Results
Akt hyperphosphorylation in Mahlavu HCC cells
Hyperactivation of Akt was previously reported in HCC
[17]. Therefore, we sought first to analyze the Akt levels
and its serine-473 phosphorylation in hepatoma cells. Akt
total amount seems comparable albeit a slight higher
expression could be observed in Mahlavu cells when
compared to Huh7 and HepG2 cells (Fig. 1a). In addition,
significant Akt phosphorylation was detectable in Mah-
lavu cells, whereas only a slight Akt phosphorylation was
detectable in HepG2 and Huh7 cells under native
conditions.
Therefore, our initial observation suggested that the poorly
differentiated Mahlavu cell line might have hyperactivated
Akt signaling in comparison to the well-differentiated HCC
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cell lines; Huh7 and HepG2 [18]. To further assess whether
Akt hyperphosphorylation in Mahlavu cells is related to the
hyperactivation of its kinase enzymatic activity, we per-
formed a kinase assay on the fusion protein GSK3
containing Akt target-phosphorylation residues. The results
of this assay (Fig. 1b) showed the presence of a very low
intrinsic activity in Huh7 cells, an intermediate activity in
HepG2 cells but a very high kinase activity in Mahlavu cells.
As a control for equal loading, samples of immunoprecipi-
tated total Akt for the kinase assay were used. These data
correlate very well with those obtained by western blot data
on p-Akt (Fig. 1a).
We sought to further verify Akt pathway activation on a
native target of Akt. To this end, we analyzed the
phosphorylation status of BAD, a well-known protein
downstream of Akt, whose phosphorylation prevents cells
from undergoing apoptosis and confers them a proliferative
advantage. The p-BAD antibody used in our study was
specific to the Ser136 target of Akt kinase. In this way we
excluded the possibility of BAD being phosphorylated by
other kinases such as Erk-p90RSK kinase, which targets
Ser122 [19]. pSer136-BAD was absent in Huh7 cells, and
barely detectable in HepG2 cells, whereas a high level of
pSer136-BAD was detected in Mahlavu cells (Fig. 1c).
Interestingly, total BAD protein levels were not equal in the
cell lines analyzed although each lane contained 20 μg of total
cell lysate, in particular Mahlavu showed lower BAD protein
levels than HepG2 (Fig. 1c). However, we observed an
intense phosphorylation by endogenous BAD in this cell
line, which might explain the faint pSer136-BAD band in
HepG2.
Determination of IC50 values for the HCC cells with SRB
cytotoxicity assay
After the analysis of the hyperphosphorylation state of the
Akt protein in well differentiated Huh7, HepG2 cells and
poorly differentiated Mahlavu cells under native conditions,
we decided to see the effect of PI3K inhibitors (LY294002,
Wortmannin) and the specific Akt inhibitor (Inhibitor VIII)
on this signaling pathway. Akt Inhibitor VIII selectively
prevents Akt1 and Akt2 activity through pleckstrin homol-
ogy (PH) domain [20, 21].
Initially we assessed their cytotoxicity by NCI-60
conventional Sulforhodamine B assay that was performed
in quadruplicate and for 5 different concentrations follow-
ing the NCI’s drug screening protocol. The inhibitory effect
of each drug of treatment was plotted (Fig. 2). IC50 values
were calculated from these graphs for 24, 48, and 72 h
(Fig. 2). IC50 values of LY294002 were 3.65 μM,
25.03 μM and 7.19 μM for 24 h and 3.75 μM, 5.82 μM
and 8.71 μM for 72 h in Huh7, HepG2 and Mahlavu cell
lines, respectively. For Wortmannin IC50 values in Huh7,
HepG2 and Mahlavu cell lines were 26.07 μM, 29.23 μM
and 20.19 μM for 24 h and 17.78 μM, 11.27 μM and
36.88 μM for 72 h, respectively. For 24 h, the IC50 values
of Inhibitor VIII were 4.42 μM and 17.16 μM for Huh7
and HepG2, while there was not a significant inhibition
observed in Mahlavu with NCI-60 assay. For 72 h, the IC50
values of Inhibitor VIII were 5.27 μM, 4.48 μM and
9.04 μM for Huh7, HepG2 and Mahlavu cells, respectively.
Real-time, dynamic monitoring of cell growth in HCC cells
treated with the inhibitors
In order to further analyze if the growth inhibition of HCC
cells is permanent or temporary, we used a novel cell
surveillance system to monitor real-time, dynamic changes
in cell growth based on the electrical impedance measure-
ment technique. The RT-CES system allowed us to monitor
the effects of LY294002, Wortmannin, and Inhibitor VIII
on the hepatoma cells by a label-free and a real-time native
approach. The proliferation and cytotoxicity of the inhib-
itors were followed by real-time through electronic cell
sensors, integrated in the bottom of the 96 E-Plates in
triplicates with 5 different concentrations (40 μM, 20 μM,
10 μM, 5 μM, 2.5 μM) (Fig. 3). When normalized to
a MVHepG2Huh7
Akt tot
p-Akt tot
β-actin
b Huh7 HepG2 MV
p-GSK3
Akt 
pSer136-Bad
Huh7 HepG2 MV
Bad tot
c
Fig. 1 Akt activity analysis in HCC cell lines. aWestern blot analysis
of untreated Huh7, HepG2, and Mahlavu cell lines, detected with anti
Akt antibody or anti-p-Akt antibody. b Kinase assay on the fusion
protein of GSK3α/β added to the reaction mixture as an exogenous
substrate. As a control for equal loading, samples of immunoprecipi-
tated Akt for the kinase assay were used. c Western blot analysis of
untreated HCC cell lines was performed with anti-total BAD antibody
or anti-p-BAD antibody. 20 μg of proteins were loaded for each lane.
Data given here are representative of three independent experiments.
SDS are less than 10%. The Mahlavu cell line displays high a Akt
phosphorylation level and the highest enzymatic activity tested on
both exogenous (GSK3α/β) and endogenous (BAD) substrate
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DMSO treated cell proliferation curves the cell growth plots
demonstrated the concentration- and time-dependent cyto-
toxic effect of the inhibitors. In addition to provide also a
visual demonstration of the effects of these drugs on these
cells we treated cells with inhibitors and show their
morphological changes by light microscope images at 24
and 48 hours in parallel with the RT-CES experiments with
IC50 of 24 hours concentrations (Fig. 3b).
High dose treatment of LY294002 (40 μM) suppressed
cell growth permanently after 8 h and continuing up to 84 h
in Huh7 and Mahlavu cell lines. Lower doses (5 μM,
2.5 μM) of LY294002 had a minor effect on cell growth for
up to 48 h but then the cells resumed growth, especially in
the case of the Mahlavu cell line. With Inhibitor VIII
treatment, cells responded similarly as to LY294002
exposure although Inhibitor VIII appeared more effective
at short exposure times. Wortmannin treatment was effec-
tive in inhibiting cell growth only for about 24 h and then
the cells gradually resumed normal growth. This real-time
dynamic continuous analysis of cell growth and toxicity
was essential to determine the optimal time points for
performing biochemical endpoint assays. The continuous,
dynamic analysis of cell growth of LY294002, Wortmannin
and Akt Inhibitor VIII treated Huh7 and Mahlavu cells
supported the time- and concentration-dependent effects of
the three inhibitors on HCC cells as shown in Fig. 2.
We also analyzed Akt enzyme activity in the presence of
inhibitors. The IC50 values of 72 h for LY294002,
Wortmannin and Akt Inhibitor VIII were used to assess
the effects of drug treatments on Akt kinase activity in
HCC cell lines by a specific kinase assay using the fusion
protein fusion protein of GSK3α/β as substrate similarly to
that of Fig. 1b. Our results demonstrated the inhibitory
effect of the three drugs on the kinase activity of the Akt
protein, when compared to the kinase assay under native
conditions. In all cases no Akt phosphorylation activity was
Fig. 2 Inhibitory effects of LY294002, Wortmannin and Akt Inhibitor
VIII on HCC cell growth. % inhibition of cell growth after a 24, b 48,
c 72 and d 96 hours of treatment with the inhibitors. Sulforhodamine
B (SRB) colorimetric assay was performed in quadruplets with 5
different concentrations (50 μM, 15 μM, 10 μM, 5 μM, 1 μM)
represented with error bars (Supplementary Figs. 1–3). The growth
inhibitory effect for shorter exposure is relevant also for low
concentrations. At longer exposure times growth inhibition requires
higher drug concentrations. IC50 values were calculated based on the
logarithmic regression line fitted on the % inhibition vs. log
(concentration) graph, Huh7 ( ), HepG2 ( ), Mahlavu ( )
Invest New Drugs (2011) 29:1303–1313 1307
detected on the fusion protein of GSK3α/β (data not
shown). These data indicate a very low Akt activity in each
cell line, evidence of a significant inhibition of the pathway
by these inhibitory molecules in HCC cells.
Cytotoxic effect of drugs on HCC cells through apoptosis
It is a well-documented fact that the Akt pathway has an
important anti-apoptotic role in different cells [22, 23].
Morphological changes specific to apoptosis can be
observed quite early after apoptotic stimuli [24, 25]. In
order to see the morphological changes in Huh7, HepG2
and Mahlavu cells after treatment with each drug, cells
were treated with inhibitors for 24 and 48 h. Each drug was
used at its IC50 value obtained after 24 h of treatment.
Apoptotic cells usually exhibit extensive DNA cleavage
during the early stages of this controlled cell death
mechanism. Cleavage may produce double-stranded, low
molecular weight DNA fragments as well as single-
stranded high molecular weight DNA fragments that
manifests themselves as condensed aberrant nuclei, as
shown by DAPI (Fig. 4) and the Hoechst 33258 stain (data
not shown). This observation demonstrated that those cells
displayed the type of cell death that is specific to apoptosis.
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Fig. 3 Cell growth of LY294002, Wortmannin and Akt Inhibitor VIII
treated Huh7 and Mahlavu cells. a Cell growth is assessed with the
xCELLigence system that measures electrical impedance across
micro-electrodes integrated on the bottom of tissue culture E-96
plates. Impedance measurements are displayed as Cell Index (CI)
values, providing real-time quantitative information on cell growth.
The effect of the inhibitors on cell growth is calculated as CIDRUG/
CIDMSO. The cell growth assay was performed in triplicates with 5
different concentrations 40 μM, 20 μM, 10 μM, 5 μM, and 2.5 μM.
Huh7-LY294002 ( ), Huh7-Akt Inhibitor VIII ( ), Huh7-
Wortmannin ( ), Mahlavu-LY294002 ( ), Mahlavu-Akt In-
hibitor VIII ( ), Mahlavu-Wortmannin ( ). b Analysis of
apoptosis associated morphological changes with light microscopy.
Huh7 and Mahlavu cells were treated with the indicated inhibitors at 24
and 48 hours. Huh7 cells : LY294002 (4 μM), Wortmannin (26 μM),
Akt Inhibitor VIII (4.5 μM) ; Mahlavu cells : LY294002 (7 μM),
Wortmannin (20 μM), Akt Inhibitor VIII (10 μM). 20X pictures were
taken with OLYMPUS CKX41 microscope with DP72 camera
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The pro-apoptotic effect of the drugs was assessed by
counting aberrant nuclei in DAPI stained cells. The
morphological features of apoptosis, i.e. condensation of
chromatin and fragmentation of the nucleus, were exam-
ined. Control cells showed rounded and homogeneous
nuclei, whereas drug treated-cells showed condensed and
fragmented nuclei (Fig. 5a). The percentage of apoptosis
ranged from 32% to 25% in Huh7, from 32% to 27% in
HepG2 and from 35% to 28% in Mahlavu, (Fig. 4b).
In order to further clarify the type of cell death
mechanism and the morphological changes that we observe
in Figs. 3b, 4a, in the presence of the inhibitors as
apoptosis, we performed Poly ADP-ribosyl polymerase
(PARP) cleavage analysis by western blot. Huh7, HepG2
and Mahlavu cells were treated with each drug at the
24hours-IC50. PARP is typically cleaved from 113 kDa to
89 and 24 kDa fragments by caspase-3 during apoptosis.
Although cleaved PARP is also detected during necrosis,
the cleaved product’s molecular size is different (50 kDa).
As shown in Fig. 5, the cleaved band (89 kDa) is due to
apoptosis, not necrosis [26]. Our observations clearly
demonstrated that Akt pathway inhibitors had an
apoptosis-dependent cytotoxic effect on HCC cell lines.
Comparative analysis of PTEN in HCC cells
With the aim of identifying differential responses of HCC
cells to Akt pathway inhibitors, we further investigated
PTEN, another pathway related molecule. PTEN protein
expression in HCC cell lines exhibited differential expres-
HepG2
Huh7
b
MV
untreated DMSO Doxo LY294002 Wort Inh VIIIa
Fig. 4 DAPI staining showing the aberrant nuclear DNA due to the
apoptotic cells with condensed nuclei (white arrows) in the presence
of inhibitors with IC50 concentrations. a The pro-apoptotic effect of
Akt pathway inhibitors on the morphology of the nuclear chromatin in
HCC cells. Cells were treated for 24 h with the IC50 values (Huh7 :
LY294002 (4 μM), Wortmannin (26 μM), Akt Inhibitor VIII
(4.5 μM); HepG2 : LY294002 (25 μM), Wortmannin (29 μM), Akt
Inhibitor VIII (18 μM); Mahlavu : LY294002 (7 μM), Wortmannin
(20 μM), Akt Inhibitor VIII (10 μM)), then fixed and stained with
DAPI. No changes were induced by DMSO. All samples treated with
the positive control, Doxorubicine (100 ng/ml) showed evident
apoptotic nuclei. Well markable, even if less present, are apoptotic nuclei
after apoptosis induction with each drug. The results were from one
experiment representative of three experiments. Bar=10 μm b Apoptotic
cells were quantified by counting a minimum of 4 fields containing at
least 150 cells. The results are presented as the mean of three
independent experiments. Doxorubicine, an inhibitor of enzyme top-
oisomerase II progression by intercalation of DNA, induced a marked
percentage of apoptosis. The three inhibitors used in this study within
each cell line, gave similar results. SD was less then 10%
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sion patterns, ranging from marked expression in the Huh7
and HepG2 cell lines, to the absence of PTEN expression in
Mahlavu cell line. The absence of PTEN protein expression
was in correlation with the hyperphosphorylation of Akt,
higher kinase activity on exogenous GSK3α/β fusion
protein and on endogenous BAD protein in Mahlavu cell
line. In correlation with the absence of PTEN protein
expression, the Mahlavu cell line had mRNA expression
with a partial deletion in the PTEN gene in exon 4 (Fig. 6),
which may explain the lack of protein that results in the
hyperactivation of the Akt protein in this cell line.
Discussion
In this study, we have shown hyperactivation of the Akt
protein in hepatoma cell lines and apoptosis induction in
time- and dose- dependent manners after treatment with
three specific inhibitors of the PI3K/Akt pathway. The
PI3K/Akt signaling pathway plays a significant role in
carcinogenesis and drug resistance in different types of
cancer including HCC, making Akt a potential target for
cancer treatment [28, 29].
Tumors with activated PI3K/Akt signaling have been
shown to become more aggressive, and Akt pathway
activation has been identified as a significant risk factor
for early disease recurrence and poor prognosis in HCC
patients [30, 31]. Activated Akt correlates also with local
metastasis of tumor cells from the primary liver cancer into
the circulatory system and the survival of the circulating
cells without cell-substratum interaction [32], showing the
significance of this hyperactivated pathway not only in liver
tumor aggressiveness but also in tumor diffusion and
survival in different environments. Therefore we initially
examined total Akt protein and native p-Akt levels in HCC
cell lines. Mahlavu cells were previously reported to be
poorly differentiated when compared to the well-
differentiated “hepatocyte-like” Huh7 and HepG2 cells
[18]. Although the cell lines included in this study showed
similar total Akt protein expression (Fig. 1a), only Mahlavu
cells displayed hyperphosphorylated Akt protein (Fig. 1a),
which was determined by anti-p473Ser-Akt antibodies,
because Ser473 Akt phosphorylation is a requirement for
full Akt enzyme activity [33]. In Mahlavu cells, in parallel to
the hyperphosphorylation of Akt, we also observed a lack of
PTEN protein expression (Fig. 6) and increased phosphor-
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Fig. 5 Investigation of apoptotic cell death in the presence of Akt
pathway inhibitors. Apoptosis activation was detected by means of
PARP cleavage. The antibodies used recognize both the intact form
(113 KDa) and the cleaved one (89 KDa). In each lane 20 μg proteins
were loaded. . Almost no cleavage is observable in control and
DMSO-treated samples. An evident PARP cleavage is induced by the
three inhibitors used. Each cell line induced similar PARP cleavage.
Data were representative of three independent experiments
Huh7 HepG2 Mahlavu
PTEN
Calnexin
Huh7 HepG2 Mahlavu
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Fig. 6 Differential expression
of the PTEN gene in human
HCC cell lines. a Whole-cell
lysates (40 μg) were analyzed
by Western blotting using anti-
PTEN antibody. Mahlavu cell
line has no PTEN expression. b
PCR analysis of PTEN gene in
HCC cell lines. Figure describes
the loss of PTEN gene fragment.
The gene fragment that is
lacking is located within exon
4 and 5
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ylation of the downstream protein Bad on Ser136 and of the
exogenous GSK3 substrate (Fig. 1b and c).
The activation of PI3K/Akt signaling frequently related
to PTEN mutation has also been observed in nearly 50% of
HCC [34], suggesting the importance of this pathway, since
tumors with hyperactive Akt due to PTEN loss depend on
hyperactivated Akt signaling for growth and survival [10].
Indeed, our results support the observations that a PTEN
deficient cell line Mahlavu has hyperactivated Akt protein.
Moreover Mahlavu has the higher IC50 values for
Wortmannin than well differentiated Huh7 and HepG2 cell
lines.
The great majority of protein kinase inhibitors that have
been developed, bind at or near the ATP binding site [35].
These compounds were recommended for use in a
concentration range of 0,1 to 100 μM to assess the roles
of particular protein kinases. Depending on concentration,
kinase inhibitors may act as multi-kinase inhibitors.
Therefore in our study we analyzed the PI3K/Akt signaling
inhibitors with concentrations between 40 μM–2.5 μM
(Figs. 2 and 3) in order to identify their specific IC50
values on hepatoma cell lines. We think that with the
concentration we used LY294002 and Wortmannin exhibit
their cytotoxic activity through binding to the proximity of
the active sites of their target kinases. Structural analysis of
the p110γ isoform of PI3K in the presence of LY294002
demonstrated that this inhibitor binds to the active site. Cell
death induced by LY294002 is through GSK3β activity,
which is also demonstrated in the presence of lithium, a
known inhibitor of GSK3β [36, 37]. Consistent with the
structural similarity between the PI3K and mTOR kinase
domains, LY294002 and Wortmannin act on both of these
kinases with similar IC50 values [38]. Both PI3K and
mTORC2 are the upstream proteins of the Akt pathway.
Therefore, we focused also on the downstream analysis of
Akt protein activation/inhibition regardless of the direct
targets of LY294002 and Wortmannin in HCC cells. To
stress the importance of Akt pathway signaling inhibition as
a potential therapeutic target in liver cancer, we analyzed
the effects of the selective Akt inhibitor, Akt Inhibitor VIII
on HCC cells [20, 21].
We applied two different cytotoxicity assays, conven-
tional NCI-60 method and novel RT-CES system. Both
assays resulted in similar IC50 values for 24, 48, and 72 h
for the specific PI3K/Akt signaling inhibitors LY294002,
Wortmannin, and Akt inhibitor VIII, although it is possible
to calculate IC50 for each time point with RT-CES. As
expected, we were able to demonstrate that all three
inhibitors had cytotoxic activity. At 24 h all three cells
had comparable IC50s but with longer treatment times
Mahlavu cells displayed higher IC50s when compared to
Huh7 and HepG2 cells. RT-CES analysis demonstrated that
normal cell growth has a cell index (CI) of around 1.2
(Fig. 3a). 20 μM inhibitor treatment did not influence the
cell proliferation during the initial 10–16 h. The cytotoxic
effect of the inhibitors became established toward the end
of the 24 h (Fig. 3a, 40–10 μM) as it can be observed by
the CI of 0.5. Between 36 h and to 60 h RT-CES data
demonstrated whether they inhibit cell proliferation irre-
versibly or whether cells can survive afterwards. In the case
of LY294002 and Akt inhibitor VIII, CI approached to 0.2
at the 60th hour meaning almost no cells attached to the
bottom of the cell culture plates to form colonies. We
confirmed this data in parallel experiments by direct light
microscopy visualization of the cells at 24 and 48 h
(Fig. 3b). Cells treated with Wortmannin displayed a
similar growth curve with CI during first 24 h to that of
LY294002 and Akt inhibitor VIII did. However starting
from 36 h both Huh7 and Mahlavu cells continued to
proliferate and expanded to cover the bottom of the E-
plate parallel to the DMSO treated control cells even with
very high (40 μM) concentrations. We confirmed again by
microscopy that the cells presented a healthy morphology
(Fig. 3b).
Continuous very low Cell Index data (0.2–0.3) with
LY294002 and Akt inhibitor VIII treatments on the
hepatoma cells were the indications of apoptotic cell death.
In addition direct light microscopy visualization of the cell
morphology showed that all the inhibitors induced apoptosis
on hepatoma cells. From the above evidence the nature of
the cell death exhibited in the presence of the PI3K/Akt
signaling inhibitors LY294002, Wortmannin, and Akt inhib-
itor VIII was characterized as apoptosis (Figs. 4 and 5).
The three drugs, generated a PARP cleavage process on
the HCC cell lines after being administered (Fig. 5). As
shown above, the drugs appear to have similar apoptotic
effects in all the cell lines tested. In addition, since PI3K-Class
IIIs control autophagic proteolysis, we examined the possi-
bility that the cytotoxic effect of these inhibitors might be
through autophagy [27]. After 48 h of incubation with the
three inhibitors we performed western blot analysis of
autophagy related proteins BECN1 and p62 but did not
observe any alterations that could be attributed to autophagy
(data not shown).
This study suggests that targeting the PI3K/Akt signaling
pathway provides a promising strategy for designing
molecular targeted therapy in the case of solid tumors,
especially HCC. Our data also suggest that PI3K/Akt
activation status serve as a biomarker for identifying
candidate patients for treatment with inhibitors of PI3K
and/or of its downstream targets. However, it should be
noted that drug transporters or IAPs (Inhibitors of Apopto-
sis Proteins) could contribute to the therapeutic resistance.
Likewise, transcription factors, such as NF-κB, can up-
regulate transporters like MRP2 to induce multidrug
resistance in HCC [39]. Furthermore, we have previously
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shown that during liver tumorigenesis HCC cells develop a
“survivor phenotype” independent of the cause of onco-
genic transformation under oxidative stress conditions [40].
It may also be important to raise questions about the
stability of the drugs for longer treatments. We performed
experiments, by monitoring cell growth real time, that
demonstrated that when drug concentration increases,
growth inhibition lasts longer. This observation could be
due to a lower a decay rate of active drug molecule
concentration. Our results obtained by the three PI3K/Akt
pathway inhibitors used clearly demonstrated that the Akt
pathway can still be a target when Akt and BAD are
hyperphosphorylated and the PTEN protein is impaired, as
we show in the Mahlavu cell line. In treatment, chemo-
therapeutic agents are usually given in a protocol with
repeating dosages to target resistant cell populations.
Tumors with hyperactive Akt due to PTEN loss depend
on Akt signaling for growth and survival [10]. Activated
Akt pathway confers resistance to cancer therapy, making
Akt a promising target for cancer treatment [34]. Increasing
knowledge in the molecular mechanisms underlying hep-
atocarcinogenesis and the advent of molecular targeted
therapies provide a promising treatment approach for HCC
patients. Novel therapeutic targets, molecular oncogenic
mechanisms and signaling cascades responsible for tumor
growth should be investigated together with potential
chemotherapeutic agents to improve clinical efficacy.
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